184 related articles for article (PubMed ID: 17967299)
1. Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome.
Evans SM; Du KL; Chalian AA; Mick R; Zhang PJ; Hahn SM; Quon H; Lustig R; Weinstein GS; Koch CJ
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1024-31. PubMed ID: 17967299
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia in human intraperitoneal and extremity sarcomas.
Evans SM; Hahn SM; Magarelli DP; Zhang PJ; Jenkins WT; Fraker DL; Hsi RA; McKenna WG; Koch CJ
Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):587-96. PubMed ID: 11173159
[TBL] [Abstract][Full Text] [Related]
3. EF5 binding and clinical outcome in human soft tissue sarcomas.
Evans SM; Fraker D; Hahn SM; Gleason K; Jenkins WT; Jenkins K; Hwang WT; Zhang P; Mick R; Koch CJ
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):922-7. PubMed ID: 16458778
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia and necrosis in rat 9L glioma and Morris 7777 hepatoma tumors: comparative measurements using EF5 binding and the Eppendorf needle electrode.
Jenkins WT; Evans SM; Koch CJ
Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):1005-17. PubMed ID: 10705024
[TBL] [Abstract][Full Text] [Related]
5. Detection of individual hypoxic cells in multicellular spheroids by flow cytometry using the 2-nitroimidazole, EF5, and monoclonal antibodies.
Woods ML; Koch CJ; Lord EM
Int J Radiat Oncol Biol Phys; 1996 Jan; 34(1):93-101. PubMed ID: 12118570
[TBL] [Abstract][Full Text] [Related]
6. Detection of hypoxia in human squamous cell carcinoma by EF5 binding.
Evans SM; Hahn S; Pook DR; Jenkins WT; Chalian AA; Zhang P; Stevens C; Weber R; Weinstein G; Benjamin I; Mirza N; Morgan M; Rubin S; McKenna WG; Lord EM; Koch CJ
Cancer Res; 2000 Apr; 60(7):2018-24. PubMed ID: 10766193
[TBL] [Abstract][Full Text] [Related]
7. 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer.
Komar G; Seppänen M; Eskola O; Lindholm P; Grönroos TJ; Forsback S; Sipilä H; Evans SM; Solin O; Minn H
J Nucl Med; 2008 Dec; 49(12):1944-51. PubMed ID: 18997048
[TBL] [Abstract][Full Text] [Related]
8. Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding.
Evans SM; Judy KD; Dunphy I; Jenkins WT; Nelson PT; Collins R; Wileyto EP; Jenkins K; Hahn SM; Stevens CW; Judkins AR; Phillips P; Geoerger B; Koch CJ
Cancer Res; 2004 Mar; 64(5):1886-92. PubMed ID: 14996753
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-inducible factor-1alpha is an intrinsic marker for hypoxia in cervical cancer xenografts.
Vukovic V; Haugland HK; Nicklee T; Morrison AJ; Hedley DW
Cancer Res; 2001 Oct; 61(20):7394-8. PubMed ID: 11606368
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models.
Chitneni SK; Bida GT; Zalutsky MR; Dewhirst MW
J Nucl Med; 2014 Jul; 55(7):1192-7. PubMed ID: 24854792
[TBL] [Abstract][Full Text] [Related]
11. Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation.
Evans SM; Hahn SM; Magarelli DP; Koch CJ
Am J Clin Oncol; 2001 Oct; 24(5):467-72. PubMed ID: 11586098
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia and VEGF mRNA expression in human tumors.
Ziemer LS; Koch CJ; Maity A; Magarelli DP; Horan AM; Evans SM
Neoplasia; 2001; 3(6):500-8. PubMed ID: 11774032
[TBL] [Abstract][Full Text] [Related]
13. The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia.
Wang J; Foehrenbacher A; Su J; Patel R; Hay MP; Hicks KO; Wilson WR
Clin Cancer Res; 2012 Mar; 18(6):1684-95. PubMed ID: 22167409
[TBL] [Abstract][Full Text] [Related]
14. Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts.
Lee J; Siemann DW; Koch CJ; Lord EM
Int J Cancer; 1996 Jul; 67(3):372-8. PubMed ID: 8707411
[TBL] [Abstract][Full Text] [Related]
15. Oxygen levels in normal and previously irradiated human skin as assessed by EF5 binding.
Evans SM; Schrlau AE; Chalian AA; Zhang P; Koch CJ
J Invest Dermatol; 2006 Dec; 126(12):2596-606. PubMed ID: 16810299
[TBL] [Abstract][Full Text] [Related]
16. Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma.
Koch CJ; Scheuermann JS; Divgi C; Judy KD; Kachur AV; Freifelder R; Reddin JS; Karp J; Stubbs JB; Hahn SM; Driesbaugh J; Smith D; Prendergast S; Evans SM
Eur J Nucl Med Mol Imaging; 2010 Nov; 37(11):2048-59. PubMed ID: 20585774
[TBL] [Abstract][Full Text] [Related]
17. Detection of hypoxic cells with the 2-nitroimidazole, EF5, correlates with early redox changes in rat brain after perinatal hypoxia-ischemia.
Bergeron M; Evans SM; Sharp FR; Koch CJ; Lord EM; Ferriero DM
Neuroscience; 1999; 89(4):1357-66. PubMed ID: 10362320
[TBL] [Abstract][Full Text] [Related]
18. Immunocytochemical labelling of aerobic and hypoxic mammalian cells using a platinated derivative of EF5.
Matthews J; Adomat H; Farrell N; King P; Koch C; Lord E; Palcic B; Poulin N; Sangulin J; Skov K
Br J Cancer Suppl; 1996 Jul; 27():S200-3. PubMed ID: 8763880
[TBL] [Abstract][Full Text] [Related]
19. Repeatability of tumour hypoxia imaging using [
Silvoniemi A; Suilamo S; Laitinen T; Forsback S; Löyttyniemi E; Vaittinen S; Saunavaara V; Solin O; Grönroos TJ; Minn H
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):161-169. PubMed ID: 29075831
[TBL] [Abstract][Full Text] [Related]
20. In situ oxygen utilization in the rat intervertebral disc.
Lee DC; Adams CS; Albert TJ; Shapiro IM; Evans SM; Koch CJ
J Anat; 2007 Mar; 210(3):294-303. PubMed ID: 17331178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
